Arcutis Biotherapeutics ( (ARQT) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Arcutis Biotherapeutics’ stock is on the rise following the FDA’s acceptance of their supplemental New Drug Application (sNDA) to expand the use of ZORYVE cream for young children. This positive development, coupled with the completion of enrollment in a Phase 2 study and a fresh marketing campaign, has led analysts to adjust their price targets. The stock’s upward movement is further supported by positive clinical data and strategic partnerships.
More about Arcutis Biotherapeutics
YTD Price Performance: 71.70%
Average Trading Volume: 2,100,356
Technical Sentiment Signal: Buy
Current Market Cap: $3.06B
For further insights into ARQT stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.